BRAF Gene Is Somatically Mutated but Does Not Make a Major Contribution to Malignant Melanoma Susceptibility: The Italian Melanoma Intergroup Study Forty-two patients with advanced thymoma or thymic ...
CAM2029 is an investigational ready-to-use, long-acting octreotide subcutaneous injection depot. Polycystic liver disease is a rare genetic disorder characterized by the progressive growth of more ...
Please provide your email address to receive an email when new articles are posted on . Adults with acromegaly who responded to treatment with an oral form of the somatostatin analogue octreotide ...
Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third most common cause of cancer mortality. Its incidence is increasing worldwide because of the dissemination of ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved an oral form of the somatostatin analogue octreotide as a long-term maintenance therapy for ...
PRESS RELEASE: Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
Company Plans to Initiate Phase III Program in First Half of 2008 LEXINGTON, Mass., Nov. 28 -- Indevus Pharmaceuticals, Inc. today announced positive results from its Phase II octreotide implant trial ...
This systematic review and meta-analysis compared 68Ga-DOTATATE positron emission tomography (PET) with 111In-DTPA-pentetreotide (octreotide) scintigraphy in patients with pulmonary and ...
May 29, 2012 (Florence, Italy) — In patients with acromegaly, long-acting-release (LAR) pasireotide (SOM230, Novartis) was more effective than octreotide LAR (Sandostatin, Novartis) at inducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback